Detalhe da pesquisa
1.
Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: updated survival results from a phase II trial (DESTINY-Breast01).
Ann Oncol
; 35(3): 302-307, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38092229
2.
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
Ann Oncol
; 34(10): 899-906, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37597579
3.
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Ann Oncol
; 33(3): 321-329, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34954044
4.
Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
Ann Oncol
; 32(2): 197-207, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33186740
5.
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases.
Ann Oncol
; 31(9): 1231-1239, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32461105
6.
TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Ann Oncol
; 31(11): 1518-1525, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32798689
7.
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Ann Oncol
; 31(5): 590-598, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32245699
8.
The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.
Ann Oncol
; 30(4): 575-581, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30753274
9.
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Ann Oncol
; 30(3): 365-373, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30715161
10.
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.
Ann Oncol
; 30(6): 927-933, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30903140
11.
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].
Ann Oncol
; 34(7): 630, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36564285
12.
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
Ann Oncol
; 33(3): 234-238, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34942341
13.
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
Ann Oncol
; 26(1): 113-119, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25355722
14.
Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancer.
ESMO Open
; 9(3): 102903, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38452436
15.
A phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.
Ann Oncol
; 24(7): 1841-1847, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23559151
16.
4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).
Ann Oncol
; 29(8): 1634-1657, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30032243
17.
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res Treat
; 139(2): 403-10, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23645007
18.
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer.
Ann Oncol
; 23(1): 93-97, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21531783
19.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Ann Oncol
; 23(9): 2399-2408, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22357447
20.
3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).
Ann Oncol
; 28(12): 3111, 2017 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28327998